Inovio Stock Story


USD 2.71  0.08  2.87%   

As many millenniums are excited about healthcare space, it is only fair to outline Inovio Pharma against current market trends. As expected, Inovio Pharma is starting to reaffirm its true potential as institutional investors are becoming more and more confident in the future outlook. Plenty of the changes of the company stock price movements has been a rough indication of what is happening in the market overall. The proof of persistent basic indicators of the company suggests a short-term price swing for institutional investors of Inovio. The stock is still going through a very aggressive trading activities.
Published over two months ago
View all stories for Inovio Pharma | View All Stories

Our latest technical analysis of Inovio Pharma (NASDAQ:INO)

The company's average rating is Hold from 8 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Inovio Pharma market sentiment investors' perception of the future value of Inovio. Let us look at a few aspects of Inovio technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Inovio Pharma. In general, we focus on analyzing Inovio Pharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inovio Pharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Inovio Pharma's intrinsic value. In addition to deriving basic predictive indicators for Inovio Pharma, we also check how macroeconomic factors affect Inovio Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inovio Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inovio Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inovio Pharma. Your research has to be compared to or analyzed against Inovio Pharma's peers to derive any actionable benefits. When done correctly, Inovio Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inovio Pharma.

How does Inovio Stands against Peers?

Analyzing Inovio Pharma competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Inovio Pharma across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Inovio Pharma Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Inovio Pharma, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by David Weiner of 11875 shares of Inovio Pharma subject to Rule 16b-3

Legal trades by Inovio Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for exercise of common stock option by David Weiner, the corporate stakeholder, on 11th of August 2022. This event was filed by Inovio Pharmaceuticals In with SEC on 2022-08-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Inovio Pharma has a beta of 1.9411. Let's try to break down what Inovio's beta means in this case. As returns on the market increase, Inovio Pharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Inovio Pharma will be expected to be smaller as well. The beta indicator helps investors understand whether Inovio Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Inovio deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity reported the last year's revenue of 1.77 M. Reported Net Loss for the year was (303.66 M) with loss before taxes, overhead, and interest of (247.47 M).

Another 3 percent rise for Inovio Pharma

Latest total risk alpha indicator falls down to -0.52. Possible price upswing?
As of the 27th of May, Inovio Pharma retains the market risk adjusted performance of (0.31), and Risk Adjusted Performance of (0.13). Inovio Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Inovio Pharma, which can be compared to its competitors. Please check out Inovio Pharma standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Inovio Pharma is priced fairly, providing market reflects its last-minute price of 1.88 per share. Please also validate Inovio Pharma total risk alpha, which is currently at (0.52) to confirm the company can sustain itself at a future point.

Whereas some companies under the biotechnology industry are still a bit expensive, Inovio Pharma may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Inovio as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Inovio Pharma.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Inovio Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to